Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer

In the past, there haven’t been many effective treatment options for advanced gynecologic cancers. Immune checkpoint inhibitors ( ICIs ) have recently received US Food and Drug Administration approval for the treatment of endometrial cancer and cervical cancer, providing some patients with long-lasting results. Numerous immunotherapy approaches are also being researched for the treatment of ovarian cancer and other gynecologic cancers, as well as earlier stages of disease. While the use of ICIs has improved patient outcomes thanks to their integration into the standard of care, it also necessitates a complex understanding of biomarker testing, treatment choice, patient selection, response evaluation and surveillance, and patient quality of life considerations. The Society for Immunotherapy of Cancer ( SITC ) gathered a multidisciplinary panel of experts to create an expert guideline for clinical practice in order to address this need for guidance. The Expert Panel developed evidence- and consensus-based recommendations to offer advice to cancer care professionals treating patients with gynecologic cancer by drawing on the published literature as well as their own clinical experience.

Published
Categorized as Oncology

Leave a Reply